Lincoln Electric Holdings, Inc. (LECO) Does 'Well,' Says Jim Cramer
Lincoln Electric Holdings, Inc. (NASDAQ:LECO) is one of the .
Lincoln Electric Holdings, Inc. (NASDAQ:LECO) is an American industrial equipment company. It makes and sells a wide variety of products that serve the needs of the oil and gas, power, construction, and other industries. As a result, Lincoln Electric Holdings, Inc. (NASDAQ:LECO)'s shares depend on industrial performance and interest rates. The stock is up by a modest 8% year-to-date after having recovered all of its post-Liberation Day losses. Cramer previously discussed the stock in January when he cautiously advised viewers to buy the stock since it had lost a lot of value. In his latest comments, the CNBC host briefly discussed the company after it rang the opening Nasdaq bell:
'Now those are two great companies. They do well. . .'
Previously in January, Cramer discussed Lincoln Electric Holdings, Inc. (NASDAQ:LECO)'s share price performance after the stock fell following the firm's earnings report:
A welder wearing protective gear, wearing a satisfied expression after completing his work.
'It did miss, it missed the revenues, okay, but you know what, this is a company that is so down from where it was, it's down 80 points. I think you can buy it. I like the company's got welding and welding is a, there are very few welders around, but that is a, that is a great manufacturer.'
While we acknowledge the potential of LECO as an investment, our conviction lies in the belief that some AI stocks hold greater promise for delivering higher returns and have limited downside risk. If you are looking for an extremely cheap AI stock that is also a major beneficiary of Trump tariffs and onshoring, see our free report on the best short-term AI stock.
READ NEXT: 20 Best AI Stocks To Buy Now and 30 Best Stocks to Buy Now According to Billionaires.
Disclosure: None. This article is originally published at Insider Monkey.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Gizmodo
21 minutes ago
- Gizmodo
RV Camping This Summer? This Power Station With Solar Panels Is at a Record Low Price
If you're heading out for camping this summer, having a reliable power station is already a smart move. But pairing your power station with a solar panel for true off-grid independence is even better—and right now, the Jackery Solar Generator 300 with a 100W panel is available at a record low price on Amazon, down by 40%. At just $298, this bundle is a steal compared to its original $499 price tag, which makes it one of the best (early Prime Day) deals you'll find for a portable solar power setup. This setup isn't just for summer adventures, either: When storms are closing in and winter looms with a threat of power loss, this power station will keep your essentials charged. See at Amazon At just 7.1 pounds, it's light enough to carry in a backpack but contains a whopping 293Wh lithium-ion battery that can supply up to 300W of clean energy. The device features two pure AC outlets so you can safely power sensitive electronics without risking voltage spikes and interference. If you desire a power station with flexibility, this model is able to charge a maximum of six devices simultaneously. The output diversity is incredible: two AC outlets, a 60W PD USB-C port (input/output compatible), a fast charge 3.0 USB-A port, and a DC car port. Recharging the Jackery Solar Generator 300 is simple: With the wall socket and the 60W PD USB-C port combined, you can top up 80% of the battery in two hours. If you're not stationary, you can use the included car charger cable or simply plug in the 100W panel for clean, green energy. The solar panel will connect with the power station seamlessly, thanks to the onboard MPPT controller. This deal is one of the best you'll find on a trusted brand like Jackery, and with the current discount, it's hard to imagine a better time to invest in this. See at Amazon
Forbes
23 minutes ago
- Forbes
Three Ideas To Boost Economic Growth And Reduce Government Deficits
NEW YORK - NEW YORK - JUNE 1: A man walks near the National Debt Clock in Midtown Manhattan on June ... More 1, 2023 in New York City. (Photo by Eduardo Munoz Alvarez/VIEWpress) The federal budget is a mess, with federal debt held by the public at $29 trillion and counting. States cannot print money and borrow the way the federal government can, but some of them still have deficit problems. Maine, California, Colorado, and New York are just a few of the states facing large deficits over the next few years. Fortunately, there are policy reforms both the federal government and state governments can implement to boost economic growth and reduce deficits. In a recent National Bureau of Economic Research (NBER) paper, economists Douglas Elmendorf, Zachary Liscow, and R. Glenn Hubbard examine several policies with the potential to increase economic growth and reduce deficits. The general idea is that increasing total factor productivity (TFP)—the primary driver of economic growth—increases incomes and thus tax revenue. If this can be done in a way that does not involve too much government spending (or revenue losses) then the higher tax revenue would lower the deficit. Using estimates from the Congressional Budget Office (CBO), the authors calculate that increasing TFP by 0.5 percentage points each year for the next decade would reduce the federal budget deficit by 1.2% of GDP and make debt held by the public around 12% of GDP lower than it otherwise would be. The authors discuss seven policies in their paper, but I am going to focus on the three that seem to have the most potential. And while the paper focuses on the policies' impacts on federal deficits, the same growth effects would also impact state budgets. The first policy idea is making it easier to build housing. Economists know land-use regulations that restrict the supply of housing—including minimum lot sizes, parking requirements, and prohibitions on apartments, duplexes, and other forms of multi-family housing—make housing more expensive. As the authors explain, reducing the cost of housing construction would lead to more housing being built, which has downstream impacts on the demand for appliances, furniture, carpet, decks, and all the other things that make a house a home. The increase in housing construction and the production of complementary products would directly increase GDP all else equal. In addition to this direct effect, more housing in the most productive cities would make it easier for workers to move to take higher paying jobs. A few studies estimate that this mobility effect would increase U.S. GDP by roughly 8%. New residents also have a significant impact on state budgets. A recent report from the National Taxpayers Union Foundation shows that adding new residents can increase a state's revenue by billions of dollars. For all these reasons, it is a good idea for policymakers to reform regulations so we can build more housing in the places people want to live. State and local governments control most of the regulations that restrict the supply of housing. Over the last several years, many states have implemented reforms to make it easier to build, including Montana, Florida, California, and Arizona. This year, Texas passed several laws that will make housing more affordable in the Lone Star state. Other states should adopt and build on these reforms. A second and related idea discussed by Elmendorf, Liscow, and Hubbard is permitting reform for construction projects. In recent years, long permitting times have gotten more attention, and for good reason. Federal laws like the National Environmental Policy Act (NEPA) can delay projects for years. A recent report from the Council on Environmental Quality, which oversees agency implementation of NEPA, found that 61% of environmental impact statements still take more than two years to review despite a law specifying a two-year deadline. Clearly, we need more changes at the federal level. States have permitting problems, too. Earlier this year, wildfires destroyed thousands of homes in Los Angeles County. California governor Gavin Newsome promised to fast-track permitting so families could rebuild and get on with their lives. Five months later, only 33 building permits have been issued and not one house has been rebuilt. This is unacceptable for a country as wealthy as the United States. Long permitting times increase project costs since money is tied up in resources—land, equipment, and buildings—that are not generating returns. As the authors note, shortening permitting times would accelerate projects already underway as well as increase the number and size of future projects by increasing the return on investment. And since reforming regulations and processes typically does not require a lot of government spending, the growth we create by shortening permitting times is likely to help bring down government deficits. A third idea to boost economic growth and help reduce government deficits is immigration reform. Allowing more foreign workers with advanced degrees in science, engineering, and math to live and work in America would increase U.S. innovation and productivity. The NBER study calculates that a one-time increase of 200,000 additional high-skill immigrants would reduce debt held by the public as a percent of GDP by 2% after thirty years. Adding more high-skilled immigrants every year instead of just a one-time increase would have a larger effect. In addition to increasing innovation and productivity, immigrants have a direct effect on government deficits. High-skill immigrants, like high-skill natives, have a positive effect on government budgets on average since they pay more in taxes than they consume in government services such as welfare benefits or Social Security. One study estimates that over a decade we could reduce federal deficits by $25 billion per 100,000 additional people who come to America to work. Another recent report from the Committee to Unleash Prosperity (CTUP) also makes the case for more immigration to increase growth. The basic formula for economic growth is to add workers and make workers more productive. The U.S. fertility rate is falling, and without a sudden rebound the best way to add workers will be through immigration. From 2013 to 2023 about half of the growth in the U.S. civilian labor force was due to immigrants, as shown in the figure below (red bar). Without immigration, U.S. labor force growth would slow and eventually turn negative. Labor force growth Immigrants also tend to be incredibly entrepreneurial. According to the CTUP report, nearly half of all Fortune 500 companies were founded by foreign-born or second-generation Americans. These immigrants and their children create jobs for native-born workers in addition to the valuable new goods and services their companies create for consumers. Federal policymakers should reform our immigration system so more high-skill immigrants can create and grow their companies in America. Government budgets throughout the United States are a mess. From cities such as Chicago to the Halls of Congress, policymakers struggle to keep spending in line with revenue. Economic growth cannot solve all these budget problems, but it can help. Policy changes that make it easier to build housing, reduce permitting times, and increase immigration would boost output, incomes, and tax revenue. If we could get government spending under control, too, we would have a real shot at fixing our debt problem.
Business Wire
23 minutes ago
- Business Wire
Acadia Pharmaceuticals Hosts Inaugural R&D Day Showcasing Pipeline and Long-Term Value Drivers
SAN DIEGO--(BUSINESS WIRE)--Acadia Pharmaceuticals Inc. (Nasdaq: ACAD) will host its inaugural 2025 R&D Day today to highlight its key pipeline programs and their potential to drive long-term growth. Across nine disclosed programs, the Company anticipates initiating seven Phase 2 or Phase 3 studies during 2025-2026. Acadia further anticipates reporting five Phase 2 or Phase 3 study readouts during 2025-2027—underscoring the breadth of its pipeline and the momentum behind its R&D strategy. Q3 2025 - Phase 2 study initiation for ACP-204 in Lewy Body Dementia Psychosis (LBDP) Q3 2025 - Phase 3 study initiation in Japan for trofinetide in Rett syndrome Early Q4 2025 - Topline results for the COMPASS PWS Phase 3 study of ACP-101 in Prader-Willi syndrome (PWS) following the recent completion of enrollment Q4 2025 - Phase 2 study initiation for ACP-211 in major depressive disorder (MDD) Q4 2025 - First in human study of ACP-271 in healthy volunteers Q1 2026 - Potential approval from European Medicines Agency for trofinetide Mid-2026 - Topline results from ACP-204 Phase 2 study in Alzheimer's disease psychosis (ADP) 2026 - Phase 2 study initiation for ACP-711 in Essential Tremor (ET) 'Acadia is building from a position of strength, with two commercial franchises on track to deliver over $1 billion in net sales this year,' said Catherine Owen Adams, Chief Executive Officer. 'As we advance our pipeline, the five molecules we showcase today represent a multibillion-dollar incremental revenue opportunity. They also underscore our unwavering commitment to bold science and our focus on delivering transformative therapies for patients with serious and underserved neurological and rare diseases. We believe the opportunity ahead is extraordinary—and we are confident in our ability to execute with discipline and purpose as we work to build a biotech powerhouse.' 'At Acadia, we're building a strong, sustainable pipeline focused on progressing the most promising science with the goal of meaningfully improving patient care,' said Elizabeth H.Z. Thompson, Ph.D., Executive Vice President, Head of R&D. 'Our pipeline is moving forward with real momentum. Between now and the end of 2026, we plan to initiate seven Phase 2 or 3 studies, with five key readouts anticipated by the end of 2027. We remain deeply committed to advancing care in neurological and rare diseases, leveraging our development expertise and commercial strength to bring meaningful innovation to patients.' The Company will be discussing the following pipeline programs today: ACP-101 (intranasal carbetocin) A long-acting analogue of human oxytocin for the potential treatment of PWS ACP-204 A new, highly selective, potent inverse agonist of 5-HT2A that builds upon lessons learned from pimavanserin for the potential treatment of ADP and LBDP ACP-211 An orally administered, selectively deuterated form of R-Norketamine for the potential treatment of MDD ACP-711 A selective GABA A -α3 modulator targeting the potential treatment of ET ACP-271 A GPR88 agonist for the potential treatment of Tardive Dyskinesia and Huntington's Disease To register for the live webcast, please click here. A replay of Acadia's R&D Day will be available on the company's website, under the investors section for approximately 3 months following the event. About Acadia Pharmaceuticals Acadia is advancing breakthroughs in neurological and rare diseases to elevate life. Since our founding we have been working at the forefront of healthcare to bring vital solutions to people who need them most. We developed and commercialized the first and only FDA-approved drug to treat hallucinations and delusions associated with Parkinson's disease psychosis and the first and only approved drug in the United States and Canada for the treatment of Rett syndrome. Our clinical-stage development efforts are focused on Prader-Willi syndrome, Alzheimer's disease psychosis and multiple other programs targeting neuroscience and neuro-rare diseases. For more information, visit us at and follow us on LinkedIn and X. Forward-Looking Statements This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Forward-looking statements include all statements other than statements of historical fact and can be identified by terms such as 'may,' 'will,' 'should,' 'could,' 'would,' 'expects,' 'plans,' 'anticipates,' 'believes,' 'estimates,' 'projects,' 'predicts,' 'potential,' 'continue,' 'opportunity,' 'goal' and similar expressions (including the negative thereof) intended to identify forward-looking statements. Forward-looking statements contained in this press release, include, but are not limited to, statements about: (i) our business strategy, objectives and opportunities, including the timing for and clinical and market potential of our pipeline assets, and potential for enhanced shareholder value; (ii) plans for, including timing, development and progress of commercialization or regulatory timelines for our products, including NUPLAZID and DAYBUE, and our product candidates; (iii) benefits to be derived from and efficacy of our products, including the potential advantages of our products and product candidates; (iv) the timing and conduct of and topline results for our clinical trials, including the timing of topline results from our clinical trial in Prader-Willi syndrome, the continuing enrollment in our clinical trials in Alzheimer's disease psychosis, the initiation of our clinical trial in Lewy Body Dementia Psychosis, and the timing and content of our presentations or announcements regarding our clinical trials; (v) our estimates regarding our future financial performance, profitability, capital requirements or expenses, including estimates of potential commercial product and pipeline peak sales and potential net sales of our commercial franchises in 2025, and (vi) our ability to successfully complete additional business development transactions. Forward-looking statements are subject to known and unknown risks, uncertainties, assumptions and other factors that may cause our actual results, performance or achievements to differ materially and adversely from those anticipated or implied by our forward-looking statements. Such risks, uncertainties and other factors include, but are not limited to: our dependency on the continued successful commercialization of our products and our ability to maintain or increase sales of our products; our plans to commercialize DAYBUE globally and trofinetide in the EU; the costs of our commercialization plans and development programs, and the financial impact or revenues from any commercialization we undertake; our ability to obtain necessary regulatory approvals for our product candidates and, if and when approved, market acceptance of our products; the risks inherent with product candidate development, including risks of unsuccessful clinical trial enrollment and negative or inconsistent results; our dependence on third-party collaborators, clinical research organizations, manufacturers, suppliers and distributors; the impact of competitive products and therapies; our ability to generate or obtain the necessary capital to fund our operations; our ability to grow, equip and train our specialized sales forces; our ability to manage the growth and complexity of our organization; our ability to maintain, protect and enhance our intellectual property; and our ability to continue to stay in compliance with applicable laws and regulations. Given the risks and uncertainties, you should not place undue reliance on these forward-looking statements. For a discussion of these and other risks, uncertainties and other factors that may cause our actual results, performance or achievements to differ, please refer to our annual report on Form 10-K for the year ended December 31, 2024 as well as our subsequent filings with the Securities and Exchange Commission from time to time, including our quarterly report on Form 10-Q for the quarter ended March 31, 2025. The forward-looking statements contained herein are made as of the date hereof, and we undertake no obligation to update them after this date, except as required by law.
